Lexaria Advances DehydraTECH With 100% GI AE Reduction, Market to Reach $180B
LEXX•Lexaria’s DehydraTECH™ delivery cut gastrointestinal side effects by up to 100% in oral GLP-1 tests and launched two new animal studies on retatrutide and amycretin. Industry forecasts lifted GLP-1 sales projections to $139 billion by 2030 and $180 billion by 2035 as Wegovy pill prescriptions reached three million.
1. DehydraTECH Reduces Gastrointestinal Adverse Events
In preclinical oral dosing tests, Lexaria’s DehydraTECH™ delivery technology achieved up to 100% reductions in gastrointestinal adverse events compared to control formulations of Rybelsus®, semaglutide, tirzepatide and liraglutide, positioning its platform as a potential safety enabler for GLP-1 therapies.
2. Expansion of DehydraTECH Pipeline
Lexaria has initiated two new animal studies this year under its DehydraTECH™ program to assess compatibility with retatrutide and amycretin, expanding its patent-protected pipeline of GLP-1 delivery enhancers and side-effect mitigators.
3. GLP-1 Market Forecasts Surge
Analysts have raised GLP-1 sector revenue forecasts to $139 billion by 2030 and $180 billion by 2035, driven by three million Wegovy® pill prescriptions since January and emerging oral therapies, underscoring a rapidly expanding market for improved drug delivery technologies.
4. Competitive Landscape Highlights Opportunity
Novo Nordisk’s global roll-out of Wegovy® pills and Eli Lilly’s Phase 3 data showing 28.3% average weight loss and substantial co-morbid improvements highlight strong demand for oral GLP-1 solutions, creating opportunities for Lexaria’s side-effect reduction platform.
